Respiratory Department, Tianjin Medical University General Hospital, Tianjin, China.
Thorac Cancer. 2019 Mar;10(3):437-444. doi: 10.1111/1759-7714.12948. Epub 2019 Jan 9.
Tumor necrosis factor receptor 2 (TNFR2) promotes tumor cell proliferation, activates immunosuppressive cells, and supports immune escape. However, its role in non-small cell lung cancer (NSCLC) has not been reported.
Quantitative real-time PCR and Western blotting were used to evaluate TNFR2 in three NSCLC cell lines (A549, H1299, H1975) and normal lung epithelial cells (BEAS-2B). TNFR2 was evaluated in 71 tumor tissues and 25 adjacent normal lung tissues by immunohistochemistry and analyzed with respect to clinical parameters.
The messenger RNA and protein levels of TNFR2 were significantly higher in A549, H1299, and H1975 cells than in BEAS-2B cells (P < 0.05) and differed significantly between NSCLC tissues and adjacent normal lung tissues by immunohistochemistry (P < 0.0001). TNFR2 is a independent prognostic factor in NSCLC. There have significantly differences in overall survival (OS) (P = 0.006) and disease-free survival (DFS) (P = 0.000) of NSCLC patients between TNFR2 low expression groups and TNFR2 high expression group.
TNFR2 is expressed in human NSCLC tissues and cell lines and is related to poor prognosis. TNFR2 may represent a new auxiliary index for patients with NSCLC.
肿瘤坏死因子受体 2(TNFR2)促进肿瘤细胞增殖,激活免疫抑制细胞,并支持免疫逃逸。然而,其在非小细胞肺癌(NSCLC)中的作用尚未报道。
通过定量实时 PCR 和 Western blot 检测三种 NSCLC 细胞系(A549、H1299、H1975)和正常肺上皮细胞(BEAS-2B)中的 TNFR2。通过免疫组化评估 71 例肿瘤组织和 25 例相邻正常肺组织中的 TNFR2,并分析其与临床参数的关系。
TNFR2 的信使 RNA 和蛋白水平在 A549、H1299 和 H1975 细胞中明显高于 BEAS-2B 细胞(P<0.05),且通过免疫组化在 NSCLC 组织和相邻正常肺组织中差异明显(P<0.0001)。TNFR2 是 NSCLC 的独立预后因素。TNFR2 低表达组和 TNFR2 高表达组 NSCLC 患者的总生存期(OS)(P=0.006)和无病生存期(DFS)(P=0.000)存在显著差异。
TNFR2 在人 NSCLC 组织和细胞系中表达,并与不良预后相关。TNFR2 可能成为 NSCLC 患者的新辅助指标。